These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 10480417)

  • 21. In vivo T cell activation properties of anti-T cell monoclonal antibodies.
    Ferran C; Bach JF; Chatenoud L
    Exp Nephrol; 1993; 1(2):83-9. PubMed ID: 8081961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
    Popma SH; Griswold DE; Li L
    Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and characterization of a divalent chimeric anti-human CD3 single chain antibody.
    Ma S; Thompson J; Hu H; Neville DM
    Scand J Immunol; 1996 Feb; 43(2):134-9. PubMed ID: 8633192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody.
    Arakawa F; Kuroki M; Kuwahara M; Senba T; Ozaki H; Matsuoka Y; Misumi Y; Kanda H; Watanabe T
    J Biochem; 1996 Sep; 120(3):657-62. PubMed ID: 8902633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased in vivo mitogenicity of anti-TCR/CD3 monoclonal antibody through reduced interaction with Fcgamma receptors.
    Kummer U; Zengerle U; Pischel J; Trautmann B; Mailhammer R; Sidell N
    Immunol Lett; 2001 Jan; 75(2):153-8. PubMed ID: 11137141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.
    Vossen AC; Tibbe GJ; Kroos MJ; van de Winkel JG; Benner R; Savelkoul HF
    Eur J Immunol; 1995 Jun; 25(6):1492-6. PubMed ID: 7614975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of anti-CD3 monoclonal antibodies on functional activity of lymphocytes: studies in vivo and in vitro.
    Parlevliet KJ; Chamuleau ME; Yong SL; Raasveld MH; ten Berge IJ; Schellekens PT
    Clin Exp Immunol; 1995 Feb; 99(2):155-9. PubMed ID: 7851005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.
    Woodle ES; Thistlethwaite JR; Jolliffe LK; Zivin RA; Collins A; Adair JR; Bodmer M; Athwal D; Alegre ML; Bluestone JA
    J Immunol; 1992 May; 148(9):2756-63. PubMed ID: 1533410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice.
    Wissing KM; Desalle F; Abramowicz D; Willems F; Leo O; Goldman M; Alegre ML
    Transplantation; 1999 Sep; 68(5):677-84. PubMed ID: 10507488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of polymorphic Fc receptor Fc gammaRIIa in cytokine release and adverse effects of murine IgG1 anti-CD3/T cell receptor antibody (WT31).
    Tax WJ; Tamboer WP; Jacobs CW; Frenken LA; Koene RA
    Transplantation; 1997 Jan; 63(1):106-12. PubMed ID: 9000670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties.
    Bolt S; Routledge E; Lloyd I; Chatenoud L; Pope H; Gorman SD; Clark M; Waldmann H
    Eur J Immunol; 1993 Feb; 23(2):403-11. PubMed ID: 8436176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo.
    Carpenter PA; Tso JY; Press OW; Yu X; Anasetti C
    Transplant Proc; 2000 Nov; 32(7):1545-6. PubMed ID: 11119827
    [No Abstract]   [Full Text] [Related]  

  • 33. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
    Herold KC; Burton JB; Francois F; Poumian-Ruiz E; Glandt M; Bluestone JA
    J Clin Invest; 2003 Feb; 111(3):409-18. PubMed ID: 12569167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD3 antibody-induced IL-10 in renal allograft recipients: an in vivo and in vitro analysis.
    Herbelin A; Abramowicz D; de Groote D; Naret C; Kreis H; Bach JF; Goldman M; Chatenoud L
    Transplantation; 1999 Sep; 68(5):616-22. PubMed ID: 10507478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective in vivo deletion of alloactivated TH1 cells by OKT3 monoclonal antibody in acute rejection.
    Reinke P; Schwinzer H; Höflich C; Ode-Hakim C; Döcke WD; Frei U; Volk HD
    Immunol Lett; 1997 Jun; 57(1-3):151-3. PubMed ID: 9232443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of apoptosis by anti-CD3 epsilon F(ab')2 in antigen receptor transgenic murine T cells activated by specific peptide.
    Yu XZ; Zhu L; Davis JE; Tso JY; Hansen JA; Anasetti C
    J Immunol; 1996 Oct; 157(8):3420-9. PubMed ID: 8871640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model.
    Choi I; Schmitt WE; Bähre A; Little M; Cochlovius B
    Immunol Lett; 2002 Feb; 80(2):125-8. PubMed ID: 11750044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OKT3-associated adverse reactions: mechanistic basis and therapeutic options.
    Suthanthiran M; Fotino M; Riggio RR; Cheigh JS; Stenzel KH
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):39-44. PubMed ID: 2530898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release.
    Woodle ES; Thistlethwaite JR; Ghobrial IA; Jolliffe LK; Stuart FP; Bluestone JA
    Transplantation; 1991 Aug; 52(2):354-60. PubMed ID: 1908148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.